17,261 trials
Diabetes Mellitus, Type II
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), or Serious Adverse Events (SAEs), or Hypoglycemic Adverse Events (HAE) or Withdrawals Due to…
Solid Tumor
Primary: Total Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) — 129 micrograms*hour/milliliters…
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Alzheimer's Disease
Primary: Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels. — 75.3; -45.5; -86.2; -283.0 pg/mL
Acute Leukaemia
Primary: Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability. — 72; 66; 24; 14 Participants
Alzheimer's Disease
Primary: Number of Adverse Events — 355; 302 number of AEs
Kidney Disease, Chronic
Primary: Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Modification of Diet in Renal Disease With 4 Variables (MDRD-4) — 3.04; 0.82…
Autistic Disorder
Primary: Number of Children Who Developed Autism — 1 Children who developed autism
Thrombocytopaenia
Primary: Number of Participants With Platelet Response up to Week 8 During Part 1 — 4 Participants
Pancreatic Cancer
Primary: Overall Response Rate (ORR) — 6.9 percentage of participants
Rheumatoid Arthritis
Primary: American College of Rheumatology 20 (ACR20) Response at 6 Months — 53; 87; 101 Participants
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12 — 56.0; 63.0…
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Mania
Primary: Change From Baseline in Depression Symptom Severity at 12 Weeks — 18; 17.7 Total score on CDRS-R
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants